Aurinia Pharmaceuticals
AUPH | NASDAQ
$15.48
-$0.25 (-1.59%)
At close: Nov 16, 2026, 4:00 PM ET
$15.81
+$0.33 (+2.13%)
After-hours:
Nov 16, 2026, 7:40 PM ET
Aurinia Pharmaceuticals Company Profile
Company profile explainedCompany Profile
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.
Key Executives
| Name | Position |
|---|---|
| Kevin C. Tang | Chairman & CEO |
| Michael S. Hearne | Chief Financial Officer |
| Ryan Cole | Chief Operating Officer |
| Stephen Robertson | Chief Legal Officer, Corporate Secretary & Chief Compliance Officer |
| Peter S. Greenleaf | Consultant |
| Stewart Kroll | Chief Development Officer |
| Thomas Wei | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 30, 2026 | 10-Q | Quarterly Report |
| Oct 30, 2026 | 8-K | Current Report |
| Sep 11, 2026 | 4 | Filing |
| Aug 26, 2026 | SC 13D/A | [Amend] Filing |
| Aug 25, 2026 | 4 | Filing |
| Aug 19, 2026 | 8-K | Current Report |
| Aug 06, 2026 | 10-Q | Quarterly Report |
| Aug 06, 2026 | 8-K | Current Report |
| Jun 08, 2026 | 4 | Filing |
| Jun 08, 2026 | 4 | Filing |
Aurinia Pharmaceuticals
| Country | Canada |
| IPO Date | Sep 3, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 128 |
| CEO | Kevin C. Tang |
Contact Details
#140, 14315 – 118 Avenue Edmonton,
AB T5L 4S6 Canada
Stock Details
| Ticker Symbol | AUPH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001600620 |
| CUSIP Number | 05156V102 |
| ISIN Number | CA05156V1022 |
| SIC Code | 2834 |
Recent News
- 18 days ago / zacks.comAurinia Pharmaceuticals (AUPH) Tops Q3 Earnings Estimates
- 18 days ago / businesswire.comAurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress
- 21 days ago / zacks.comEarnings Preview: Aurinia Pharmaceuticals (AUPH) Q3 Earnings Expected to Decline
- 22 days ago / zacks.comWhy Aurinia Pharmaceuticals (AUPH) is a Top Growth Stock for the Long-Term
- 25 days ago / zacks.comWhy Aurinia Pharmaceuticals (AUPH) is a Top Momentum Stock for the Long-Term
- 3 months ago / zacks.comAurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises
- 3 months ago / benzinga.comAurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug
- 3 months ago / businesswire.comAurinia Settles Patent Litigation with Teva
- 3 months ago / seekingalpha.comAurinia Pharmaceuticals Doubles Down On Its Pipeline
- 3 months ago / zacks.comAurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates
Add to Watchlist
Select watchlists to add or remove AUPH